| [1] |
Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL)[J]. Leukemia, 1995, 9(10):1783-1786.
pmid:7564526 |
| [2] |
Walker RC, Paya CV, Marshall WF, et al. Pretransplantation seronegative Epstein-Barr-virus status is the primary risk factor for post-transplantation lymphoproliferative disorder in adult heart, lung, and other solid-organ transplantations[J]. J Heart Lung Transpl, 1995, 14(2):214-221.
pmid:7779838 |
| [3] |
Nakid-Cordero C, Baron M, Guihot A, et al. Natural killer cells in post-transplant lymphoproliferative disorders[J]. Cancers (Basel), 2021, 13(8):1836. DOI: 10.3390/cancers13081836.
doi:10.3390/cancers13081836 |
| [4] |
Preiksaitis JK, Keay S. Diagnosis and management of posttransplant lymphoproliferative disorder in solid-organ transplant recipients[J]. Clin Infect Dis, 2001, 331(Suppl 1):S38-S46. DOI: 10.1086/320903.
doi:10.1086/320903 |
| [5] |
Sabattini E, Bacci F, Sagramoso C, et al. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview[J]. Pathologica, 2010, 102(3):83-87.
pmid:21171509 |
| [6] |
Fujimoto A, Suzuki R. Epstein-Barr virus-associated post-transplant lymphoproliferative disorders after hematopoietic stem cell transplantation: pathogenesis, risk factors and clinical outcomes[J]. Cancers (Basel), 2020, 12(2):328. DOI: 10.3390/cancers12020328.
doi:10.3390/cancers12020328 |
